Unilabs Announces Global Strategic Alliance in Companion Diagnostic Testing with Biogen Idec for STRATIFY- JCV
Unilabs has been selected by Biogen Idec to provide a companion diagnostic anti-JCV antibody assay test, called STRATIFY-JCV. The test is a highly sensitive two-step ELISA assay used to detect anti-JCV antibodies. The presence of anti-JCV antibodies is one in a three-factor risk stratification algorithm, along with prior immunosuppressant use and treatment duration, used to calculate the risk of TYSABRI-treated patients developing progressive multifocal leukoencephalopathy (PML).
To support customers, ordering needs and volume of samples, Unilabs and Biogen Idec have also developed a closed web interface to allow neurologists to order sampling and shipping materials, register courier sample pick up details, and request language and format of analytical reports. Also, neurologists can seek sampling, shipping and medical support in five major languages through a multilingual call centre. The project is centralised to and managed by Unilabs in Copenhagen.
Natascha Schill, Biogen Idec commented: “Unilabs is an independent commercial laboratory with a very high reputation, a strong European footprint and excellent international skills, competences and agility. We are very happy to work with Unilabs”
According to Yvonne Lech, Managing Director of Unilabs Denmark, “The experiences and the innovations created for this project can be applied in the future to create added customer value for future global Companion Diagnostic projects.”
Companion Diagnostics are expected to be the future for many new medicines. This collaboration is a clear example of this trend since it combines our distinct competencies and offers our clients a truly international high-quality service.
Unilabs - A leader in diagnostic services
Unilabs
is a leading diagnostic services company. We operate more than 100
laboratories and 30 radiology units in Belgium, Denmark, Finland,
France, Italy, Norway, Portugal, Russia, Spain, Sweden, Switzerland, and
the United Kingdom. Our customers are both public and private.
We
serve: hospitals, outpatients clinics, GPs, occupational health units,
insurance companies, drug development companies and CROs. We supply
medical laboratory analyses and services within clinical biochemistry,
haematology, transfusion medicine, microbiology, serology, immunology,
special chemistry, nuclear medicine, molecular biology, genetic testing,
histopathology, and clinical trials. Our radiology units supply services
within conventional X-ray, mammography, MRI, CT, ultrasound,
fluoroscopy, osteoporosis, nuclear medicine and teleradiology. For more
information please visit
www.unilabs.com
.
Contact:
Unilabs a.s.:
Yvonne Lech, Managing Director
Tel: +45
23 44 12 84
email: yvonne.lech@unilabs.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial 3-axis accelerometer has high offset stability24.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has introduced a 3-axis accelerometer for the industrial market that combines high offset stability over temperature and time, good linearity, low noise density, and excellent robustness. The SCA3400-D01 XYZ accelerometer is meant for use in industrial applications such as structural health monitoring (SHM), machine control, inertial measurement units, and construction tools and systems. This product will be exhibited at Sensors Converge 2025 to be held at the Santa Clara Convention Center (Booth #716), California from 24 to 26 June 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623994075/en/ [Murata Manufacturing Co., Ltd.] Industrial 3-axis accelerometer The offset stability of an accelerometer refers to the consistency of its output when at rest, but subject to varying temperatures or the effects of aging. Ideally, this output should be zero, but i
Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 15:15:00 CEST | Press release
Key Takeaways: Grid Dynamics introduces an AI-powered engagement model for software delivery. This engagement model expands Grid Dynamics’ offerings by providing a fundamentally new way of delivering value—enabling clients to achieve superior outcomes by providing the next level of agility, quality, and accelerated time-to-market. The model is based on the Grid Dynamics AI-Native Development Framework (GAIN Development Framework)—a combination of proprietary processes, human capital, and an AI-Enabled Development Platform. This framework is designed specifically to support the scale and complexity of Fortune 1000 enterprises. Based on internal benchmarks, we expect this model to accelerate project delivery by achieving over 30% productivity improvements. Progressive credit-based pricing directly tied to performance and value is the basis of the new engagement model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provid
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
Sagemcom’s Net Zero Trajectory Approved by SBTi: Target Set for 204023.6.2025 14:00:00 CEST | Press release
Sagemcom Group has today reached a critical milestone in its climate strategy: its Net Zero carbon target for 2040—encompassing all activities and sites within the Group’s consolidated scope—has been officially validated by the Science Based Targets initiative (SBTi). This international endorsement attests to the scientific rigor of Sagemcom’s decarbonization strategy, aligned with the Paris Agreement’s ambition to limit global warming to 1.5°C. It strengthens the Group’s comprehensive climate roadmap, which is built on a significant reduction of greenhouse gas emissions across all scopes: By 2030: A 47% absolute reduction in Scope 1 and Scope 2 emissions (direct emissions and purchased energy), 100% renewable energy consumption across all Group sites, A 31% absolute reduction in Scope 3 emissions, including those related to the value chain, with no exclusion of any greenhouse gas categories. By 2040: Achievement of Net Zero, corresponding to a 90% absolute reduction in total Group emi
One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row23.6.2025 14:00:00 CEST | Press release
Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International for the third consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623000452/en/ Ryan Rogers, Chief Executive Officer of Mary Kay states: "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay. This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." (Photo Courtesy: Mary Kay Inc.) Euromonitor International is the foremost provider of globa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom